HUP0001652A3 - Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them - Google Patents

Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them

Info

Publication number
HUP0001652A3
HUP0001652A3 HU0001652A HUP0001652A HUP0001652A3 HU P0001652 A3 HUP0001652 A3 HU P0001652A3 HU 0001652 A HU0001652 A HU 0001652A HU P0001652 A HUP0001652 A HU P0001652A HU P0001652 A3 HUP0001652 A3 HU P0001652A3
Authority
HU
Hungary
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
oxadiazole derivatives
Prior art date
Application number
HU0001652A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HUP0001652A2 publication Critical patent/HUP0001652A2/hu
Publication of HUP0001652A3 publication Critical patent/HUP0001652A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0001652A 1996-10-18 1997-10-15 Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them HUP0001652A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19643037A DE19643037A1 (de) 1996-10-18 1996-10-18 Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
HUP0001652A2 HUP0001652A2 (hu) 2001-01-29
HUP0001652A3 true HUP0001652A3 (en) 2002-12-28

Family

ID=7809114

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001652A HUP0001652A3 (en) 1996-10-18 1997-10-15 Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (1) US6277872B1 (hu)
EP (1) EP0934288B1 (hu)
JP (1) JP3333523B2 (hu)
KR (1) KR20000049253A (hu)
CN (1) CN1086698C (hu)
AR (1) AR008496A1 (hu)
AT (1) ATE315034T1 (hu)
AU (1) AU737552B2 (hu)
BG (1) BG103251A (hu)
BR (1) BR9714354A (hu)
CA (1) CA2268954C (hu)
CO (1) CO4920253A1 (hu)
CZ (1) CZ138099A3 (hu)
DE (2) DE19643037A1 (hu)
EE (1) EE9900147A (hu)
ES (1) ES2256880T3 (hu)
HK (1) HK1020956A1 (hu)
HR (1) HRP970553A2 (hu)
HU (1) HUP0001652A3 (hu)
ID (1) ID18613A (hu)
IL (1) IL129315A0 (hu)
NO (1) NO312512B1 (hu)
NZ (1) NZ335598A (hu)
PE (1) PE11199A1 (hu)
PL (1) PL332432A1 (hu)
RU (1) RU2182905C2 (hu)
SK (1) SK49999A3 (hu)
TR (1) TR199900848T2 (hu)
TW (1) TW413678B (hu)
WO (1) WO1998017652A1 (hu)
YU (1) YU40997A (hu)
ZA (1) ZA979220B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
TWI258472B (en) 1999-02-15 2006-07-21 Eisai Co Ltd Heterodiazinone derivatives
PT1070708E (pt) 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
EP1582519A3 (en) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
US20030225081A1 (en) * 2000-09-18 2003-12-04 Satoshi Nagato Pyridazinones and triazinones and medicinal use thereof
MXPA03007513A (es) * 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
NZ537980A (en) 2002-08-23 2007-08-31 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing HCV infection
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2006109876A1 (ja) * 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. 不随意運動治療剤
CN101203498A (zh) 2005-05-02 2008-06-18 里格尔药品股份有限公司 包括可代谢部分的杂环抗病毒化合物及其用途
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CN104478821B (zh) * 2007-10-04 2016-09-28 默克雪兰诺有限公司 噁二唑二芳基化合物
US9045442B2 (en) * 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
RU2531915C2 (ru) 2008-06-09 2014-10-27 Людвиг-Максимилианс-Универзитет Мюнхен Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания
US9095596B2 (en) * 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
BR112015003824B1 (pt) * 2012-08-24 2022-10-04 Treventis Corporation Composto, composição farmacêutica e uso do composto
DK3110812T3 (da) 2014-02-27 2019-07-08 Treventis Corp Anti-amyloidforbindelser indeholdende benzofurazan
EP3135114B1 (en) 2014-04-24 2019-03-20 Sumitomo Chemical Company, Limited Diaryl-azole compound
KR20170113529A (ko) * 2014-09-25 2017-10-12 유니버시티 오브 노트르 담 듀락 비-베타 락탐 항생제
CN107286174B (zh) * 2016-04-11 2020-08-18 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
CA3062749A1 (en) 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4403185A1 (en) 2021-09-15 2024-07-24 University of The Ryukyus Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
WO2023042887A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
EP4173485A1 (en) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
EP0276432A3 (de) * 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
JPH02250873A (ja) * 1989-03-24 1990-10-08 Mitsubishi Petrochem Co Ltd １，２，４―オキサジアゾール誘導体及びそれを有効成分とする除草剤
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
EP0596933A1 (en) * 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
DE4401107A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 3-Aryl-alkenyl-1,2,4-oxadiazol-Derivate
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest

Also Published As

Publication number Publication date
HK1020956A1 (en) 2000-05-26
BG103251A (en) 2000-02-29
ID18613A (id) 1998-04-23
US6277872B1 (en) 2001-08-21
CA2268954A1 (en) 1998-04-30
YU40997A (sh) 2000-10-30
JP2000505089A (ja) 2000-04-25
DE59712543D1 (de) 2006-03-30
KR20000049253A (ko) 2000-07-25
NO312512B1 (no) 2002-05-21
CO4920253A1 (es) 2000-05-29
AR008496A1 (es) 2000-01-19
HRP970553A2 (en) 1998-08-31
PL332432A1 (en) 1999-09-13
SK49999A3 (en) 1999-11-08
JP3333523B2 (ja) 2002-10-15
EP0934288A1 (de) 1999-08-11
AU737552B2 (en) 2001-08-23
BR9714354A (pt) 2000-04-11
ZA979220B (en) 1998-04-20
CN1233245A (zh) 1999-10-27
CN1086698C (zh) 2002-06-26
CA2268954C (en) 2006-06-13
IL129315A0 (en) 2000-02-17
DE19643037A1 (de) 1998-04-23
CZ138099A3 (cs) 1999-11-17
AU4867697A (en) 1998-05-15
RU2182905C2 (ru) 2002-05-27
NZ335598A (en) 2001-06-29
EP0934288B1 (de) 2006-01-04
WO1998017652A1 (de) 1998-04-30
HUP0001652A2 (hu) 2001-01-29
NO991815L (no) 1999-04-16
ES2256880T3 (es) 2006-07-16
ATE315034T1 (de) 2006-02-15
PE11199A1 (es) 1999-03-03
TW413678B (en) 2000-12-01
EE9900147A (et) 1999-12-15
NO991815D0 (no) 1999-04-16
TR199900848T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
HUP0001652A3 (en) Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
IL125811A (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them and uses thereof in the preparation of a composition for inhibiting nos
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
NZ304901A (en) Taxoid derivatives, preparation thereof and pharmaceutical compositions containing same
IL119994A0 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazolidinones their preparation and pharmaceutical compositions containing them
IL112193A0 (en) Phenylpyrazolopyridine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
IL98873A0 (en) Benzodiazepine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9701194A3 (en) 4-hydroxy-piperidine derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
HUP9904682A3 (en) Phenyloxazole and -thiazole derivatives, their use and pharmaceutical compositions containing them
IL112443A0 (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
IL121969A0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them
HUP9901349A3 (en) Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
HUP9800631A3 (en) 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
HUP0001873A3 (en) Amidino-1,4-benzoxazepine derivatives, process for their preparation, their use and pharmaceutical compositions containing them